MorphoSys AG acted as the seller in this Takeover transaction.
The divestment involved assets operating in the Healthcare sector.
The transaction was announced on 06 Feb 2024 with a reported value of 27000000000.0.
Generated by AI, original source from - Data is in progress
Found it useful? Spread the word.
Latham & Watkins advises Centerview Partners as lead financial advisor to MorphoSys on Novartis' $2.97 billion public takeover offer for MorphoSys AG. | The Sponsor - The Sponsor
